Drug Trial Radar · NCT00539994
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
Last checked: Nov 20, 2026Latest source record: Dec 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Sep 2007
Primary completion
Jan 2008
Study completion Jan 2008
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects who are nasally colonized with S. aureus. Approximately 57 healthy subjects who are nasal carriers of S. aureus will be enrolled and stratified in a 2:1 ratio so that at least 38 persistent carriers and 19 intermittent carriers complete the study. Each eligible subject will participate in three screening visits, a treatment period, and two follow-up visits. Each subject's participation in the study will be approximately 6 to 10 weeks from screening to the last follow-up visit. Subjects will participate in up to three screening visits to determine S. aureus culture positivity and colonization status.
Conditions
- Infections, Bacterial
Interventions
retapamulinDrug
200mg BID retapamulin 3 days
RetapamulinDrug
200mg BID retapamulin 5 days
PlaceboDrug
200mg BID placebo 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After DosingTime frame: Days 1 and 3
- Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Day 5 Evaluated by Plasma AUC After DosingTime frame: Day 5
- Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma Cmax After DosingTime frame: Days 1 and 3
- Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Day 5 Evaluated by Plasma Cmax After DosingTime frame: Day 5
- Percentage of Participants With Eradication of S. Aureus Nasal Carriage at Day 12 Who Were Categorized as Persistent Carriers of S. AureusTime frame: Day 12
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
San Diego, California
GSK Investigational Site
Honolulu, Hawaii
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.